What Is the ASXL1 Gene and Why Do Mutations Matter?

ASXL1 is a gene that acts as a master switch for how other genes get turned on and off, particularly in blood-forming cells. When ASXL1 is working correctly, it helps maintain the chemical tags on DNA-packaging proteins that keep certain genes properly silenced or active. When it picks up mutations, the consequences range from blood cancers and accelerated bone marrow aging to a rare congenital syndrome in children. ASXL1 mutations have become one of the most clinically important genetic markers in hematology over the past decade, and their reach extends further than most people realize.

What ASXL1 Does in Healthy Cells

Your DNA does not float freely inside a cell. It wraps around clusters of proteins called histones, forming a tightly packed structure called chromatin. Chemical tags placed on those histones determine whether nearby genes are accessible and active or locked away and silent. ASXL1’s primary job is to help manage those tags, making it what researchers call an epigenetic regulator. It does not change the DNA sequence itself; it changes whether parts of the sequence can be read.

ASXL1 works as part of a molecular partnership. It is the obligate regulatory subunit of a complex whose catalytic partner is an enzyme called BAP1.¹ Together, ASXL1 and BAP1 form what is known as the Polycomb repressive deubiquitinase complex, or PR-DUB. This complex removes a specific chemical tag, a ubiquitin molecule, from histone H2A at a position called lysine 119. That removal protects actively used genes from being incorrectly shut down.² Without ASXL1 switching it on, BAP1 sits in an unproductive state and cannot efficiently carry out the reaction.³

ASXL1 also participates in a second major regulatory system, the Polycomb repressive complex 2 (PRC2). PRC2 adds a different chemical mark, a trimethyl group to histone H3 at lysine 27, which silences genes that should stay off. ASXL1 helps recruit PRC2 to the right spots on the genome. When ASXL1 is lost from cells, PRC2 cannot find its targets at certain gene clusters, and those genes fire inappropriately.⁴ One of the most affected clusters is the HOXA gene family, a set of genes that orchestrate cell identity during development and blood cell production. When HOXA genes become overactive, cells can start behaving more like immature, self-renewing stem cells than the specialized blood cells they are supposed to become.

The Evolutionary Roots of the Gene

ASXL1 is not unique to humans. It belongs to a family of three related genes, ASXL1, ASXL2, and ASXL3, all of which trace back to a single ancestor gene in fruit flies called Additional sex combs, or Asx. The fly version was discovered because mutations in it caused developmental defects visible as extra bristle-like structures on male legs. Researchers later found that mammals carry three copies of this gene that have diversified in function. The mouse version of ASXL1 shares about 74% of its amino acid sequence with the human version, and both retain two structural features inherited from the fly gene: a domain near the front of the protein that helps bind to nuclear receptors, and a specialized “PHD” domain at the tail end involved in reading histone marks.⁵ This deep evolutionary conservation is part of why the gene matters so much: cells across species rely on ASXL1 for the same fundamental job of keeping chromatin properly organized.

How Mutations Break the System

Most disease-causing ASXL1 mutations are frameshift or nonsense mutations clustered in one large segment of the gene (exon 12). These mutations create a premature stop signal in the DNA code, which produces a shortened, or truncated, version of the ASXL1 protein. For a long time, researchers debated whether these truncated proteins were actually made by cells or simply degraded. That question matters because the answer determines whether the mutations cause harm by removing ASXL1 entirely (a loss-of-function effect) or by producing a broken protein that actively interferes with normal biology (a gain-of-function or dominant-negative effect).

Evidence now supports the second scenario. Researchers detected truncated ASXL1 proteins in cell lines carrying homozygous ASXL1 mutations, confirming that cells do produce the shortened protein using mass spectrometry and antibody-based detection methods.⁶ The truncated protein retains the front portion that binds BAP1 but loses the back portion, including the PHD domain that reads histone marks. The result is a deubiquitinase complex that still works, sometimes with enhanced activity, but has lost the ability to find the correct spots on chromatin. In mouse studies, cells expressing this mutant version of ASXL1 retained the capacity to replicate indefinitely in laboratory assays, while normal cells could not.⁷

Meanwhile, ASXL1 loss simultaneously disrupts PRC2’s ability to silence genes it normally keeps off. In blood-forming cells, this means developmental genes such as the HOXA cluster lose their repressive histone marks, become overactive, and push cells toward uncontrolled self-renewal. It is this dual disruption, both the misdirected deubiquitinase and the collapsed gene-silencing system, that makes ASXL1 mutations so potent.

Clonal Hematopoiesis and Aging

You do not need to have cancer for ASXL1 mutations to affect your health. As people age, their blood-forming stem cells accumulate random mutations. Occasionally, a stem cell with a particular mutation gains a growth advantage, and its descendants gradually take over a larger share of blood production. When this happens without any sign of blood cancer, the condition is known as clonal hematopoiesis of indeterminate potential, or CHIP. ASXL1 is one of the most commonly mutated genes found in CHIP, alongside DNMT3A and TET2.

What sets ASXL1-driven CHIP apart is the strength of its association with bad outcomes. Among the major CHIP genes, ASXL1 mutations carry a particularly strong link to cardiovascular disease and pro-inflammatory signatures.⁸ A large genetic study quantified the cardiovascular risk associated with different CHIP genes. ASXL1 mutations were associated with roughly a 1.4-fold increase in cardiovascular disease risk, which was exceeded only by the much rarer JAK2 mutations and was substantially greater than the risk linked to the more common DNMT3A or TET2 mutations.⁹ The mechanism likely involves inflammation: ASXL1-mutant blood cells appear to produce inflammatory signals at higher rates, creating a chronic low-grade inflammatory state that damages blood vessels over time.

Connections to Blood Cancers

ASXL1 mutations appear across a wide spectrum of blood cancers. They are found in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myeloproliferative neoplasms (MPNs) including myelofibrosis. In each of these diseases, the mutation consistently signals worse outcomes.

In MDS, a condition where the bone marrow produces abnormal blood cells, a meta-analysis of ten studies found that ASXL1 mutations were linked to shorter survival and a significantly higher risk of the disease progressing to acute leukemia.¹⁰ An earlier study that tracked MDS patients found that ASXL1 frameshift mutations remained an independent predictor of worse survival even after accounting for other known risk factors like chromosome abnormalities.¹¹

In AML, the picture is similar. Patients with ASXL1 mutations had a median survival of about 16 months compared to about 22 months for those without the mutation, and their rate of achieving complete response to initial treatment was substantially lower.¹² The European LeukemiaNet and other classification systems now include ASXL1 mutation status as part of their risk stratification for AML, meaning it directly influences treatment decisions. In younger adults with AML, the presence of ASXL1 mutation alongside a RUNX1 mutation is considered a particularly strong negative prognostic marker.¹³

In primary myelofibrosis, a meta-analysis found that ASXL1 mutations more than doubled the risk of death and were linked to higher rates of transformation to acute leukemia. These mutations were also correlated with age over 65, male sex, and lower platelet counts.¹⁴ The mutations contribute to the bone marrow scarring characteristic of myelofibrosis by driving inflammation through a pathway involving a protein called TNF-alpha, one of the body’s most potent pro-inflammatory signals.¹⁵

Why Co-Mutations Change the Prognosis

ASXL1 mutations rarely occur in isolation. They tend to appear alongside mutations in other genes, and these combinations matter for prognosis and treatment. Among MDS patients with ASXL1 mutations, the most frequently co-occurring mutations were in the RUNX1 gene, present at a rate of about 43% compared to 17% in patients with normal ASXL1.¹⁶ The combination was devastating: patients carrying both RUNX1 and ASXL1 mutations had a median survival of only 14 months and responded extremely poorly to hypomethylating agents, the standard treatment for MDS.

Other commonly co-occurring mutations include SRSF2 (a gene involved in RNA processing), STAG2 (involved in chromosome separation), and EZH2 (which, like ASXL1, is part of the Polycomb repressive system).¹⁷ When ASXL1 and EZH2 are both mutated, the gene-silencing system takes a double hit, since ASXL1 recruits PRC2 and EZH2 is PRC2’s enzymatic engine. Patients with both mutations, or with additional mutations on top of them, tend to fare worse than those with either mutation alone, though some analyses have not reached statistical significance for this comparison given the small numbers of patients involved.¹⁸

This clustering of mutations is not a coincidence. The biological systems that ASXL1 disrupts, chromatin regulation and stem cell self-renewal, create an environment in which additional mutations can accumulate more easily. A cell that has already lost proper gene silencing is more likely to tolerate further genetic damage. Clones carrying ASXL1 mutations may also be preferentially selected by cancer therapies, including chemotherapy and radiation, which can give these already-damaged cells an additional growth advantage over normal cells.¹⁹

Bohring-Opitz Syndrome and Germline Mutations

The mutations discussed so far are somatic, meaning they arise during a person’s lifetime in individual cells. But ASXL1 mutations can also be present from birth. When a child inherits or develops a new ASXL1 mutation in the germline (the DNA present in every cell of the body), the result is Bohring-Opitz syndrome (BOS), a rare and severe developmental disorder.

Children with BOS typically have severe intellectual disability, a characteristically small head, distinctive facial features including prominent eyes and a birthmark on the face, feeding difficulties, and very low muscle tone.²⁰ Most cases are caused by new, spontaneous nonsense or frameshift mutations in ASXL1, meaning neither parent typically carries the mutation. In the original study that linked the gene to the syndrome, seven out of thirteen children with clinical features of BOS were found to have de novo ASXL1 mutations, suggesting that the condition has more than one genetic cause.²¹

Rare cases of inherited BOS have been reported. In at least one documented instance, a mother who carried the ASXL1 mutation in a fraction of her egg cells (a condition called germline mosaicism) passed it to her child, even though she herself appeared clinically unaffected.²² This has implications for genetic counseling: a couple who has had one child with BOS may face a small but real risk of recurrence if the mutation is present in mosaic form in a parent.

Effects Beyond Blood Cancers

One of the more surprising recent findings is that ASXL1-mutant blood cells can influence the behavior of solid tumors, even though the mutation exists only in immune cells and not in the tumor itself. In mouse models, animals whose blood cells carried an ASXL1 mutation showed faster growth of transplanted solid tumors compared to animals with normal blood cells. The effect was traced specifically to T cells. ASXL1-mutant T cells showed abnormal development, a disturbed balance between naïve and memory cell populations, and increased expression of the exhaustion marker PD-1 on the cytotoxic T cells that are supposed to kill cancer cells. Tumors in these mice had reduced immune cell infiltration, creating a more permissive environment for tumor growth.²³

This finding has practical implications. CHIP is extremely common in older adults, and many people receiving treatment for solid cancers like breast, lung, or colon cancer may unknowingly carry ASXL1-mutant blood cell clones. If those clones are undermining anti-tumor immunity, it could partly explain why CHIP carriers tend to have worse outcomes with solid cancers. Whether this phenomenon will eventually affect treatment choices, for instance by adding CHIP screening to standard cancer workups, is still an open question, but the biology is increasingly difficult to ignore.

How ASXL1 Mutations Are Detected

Testing for ASXL1 mutations is now routine in the evaluation of blood cancers and increasingly considered in other clinical settings. The standard method is next-generation sequencing (NGS), which can read the DNA code of targeted gene regions from a blood or bone marrow sample. A typical panel for blood cancers sequences a set of genes commonly mutated in these diseases, and ASXL1, specifically its large exon 12 where most pathogenic mutations cluster, is a fixture on these panels.²⁴

One technical wrinkle that clinicians and patients should be aware of involves a specific variant sometimes detected at a single position in exon 12. This particular change is so common in sequencing results that debate has long surrounded whether it represents a true somatic mutation or a sequencing artifact introduced during sample preparation. Most clinical guidelines now recommend caution in interpreting this variant unless it is present at high levels or confirmed by an independent method. For patients receiving their NGS results, this means an ASXL1 “mutation detected” report should always be interpreted in the context of the specific variant found and its clinical significance, ideally with input from a hematologist who understands the gene’s biology.

What Happens in the Bone Marrow

In young mice engineered to carry an ASXL1 mutation, blood stem cells are actually reduced in number and impaired in their ability to repopulate blood after transplantation. Their differentiation is skewed toward the myeloid lineage, meaning they preferentially make white blood cells associated with innate immunity rather than producing a balanced mix of cell types.²⁵ With aging, however, the picture flips. The mutant stem cells gradually expand, outcompeting their normal counterparts, which explains why ASXL1-related CHIP and blood cancers are diseases of older age.

This age-dependent behavior is an important nuance. The same mutation that weakens stem cell function in a young animal can fuel clonal expansion in an older one, likely because the aging bone marrow environment, which is already more inflammatory and less supportive of normal stem cells, inadvertently favors the survival of ASXL1-mutant cells. Understanding this shift is one of the active frontiers in ASXL1 research, as it touches on broader questions about why blood cancers overwhelmingly strike later in life.

Implications for Treatment and Monitoring

For patients already diagnosed with a blood cancer, ASXL1 mutation status feeds directly into risk classification. In AML, it can influence whether a patient is recommended for more intensive therapy, including bone marrow transplantation, versus standard chemotherapy. In MDS, the combination of ASXL1 and RUNX1 mutations predicts a poor response to hypomethylating agents, which could steer clinicians toward transplant or clinical trials instead.

For people with CHIP who have not developed cancer, the picture is more uncertain. There are currently no approved therapies that target ASXL1-mutant clones directly. The cardiovascular inflammation associated with ASXL1-driven CHIP is being studied as a potential target, with interest in whether anti-inflammatory treatments could reduce the elevated heart disease risk. Some researchers are also exploring whether drugs that modulate the Polycomb system or the signaling pathways activated by ASXL1 mutations, such as the Akt/mTOR pathway identified in mouse studies, could selectively suppress mutant clones.

For families affected by Bohring-Opitz syndrome, genetic testing of the affected child confirms the diagnosis, and parental testing for mosaicism can inform recurrence risk. Management of BOS itself remains supportive, focused on feeding support, seizure control, and therapies to address developmental delay, since no treatment yet addresses the underlying epigenetic disruption caused by the germline mutation.